logo image

Entecavir information from DrugsUpdate  

See Available Brands of Entecavir in India

Entecavir, an anti-retroviral drug, is prescribed for the treatment of chronic hepatitis B infections including compensated liver diseases and uncompensated liver diseases. The drug inhibits viral replication in hepatitis B infected patients.

Pharmacodynamics

The guanosine nucleoside analogue inhibits reverse transcriptase (rt) by phosphorylation reaction into active triphosphate form. The drug prevents base priming, reverse transcription of mRNA (negative strand) and synthesis of HBV positive strand. Entecavir is a weak inhibitor of mitochondrial DNA polymerase and DNA polymerases.

Pharmacokinetics

After oral administration of Entecavir, peak plasma concentration can be achieved after 0.5 to 1.5 hours. With proportional to dosage, Cmax and AUC increase at a steady state after 6-10 days. The oral bioavailability of Entecavir is 100%. High-fat meal may delay the absorption and other pharmacokinetics of Entecavir. The terminal plasma half-life of Entecavir is approximately 128-149 hours with an accumulation half-life of approximately 24 hours. The drug is eliminated predominantly via kidneys.

Entecavir Indications / Entecavir Uses

Information not available

Entecavir Adverse Reactions / Entecavir Side Effects

Entecavir may cause serious lactic acidosis, myalgia, numbness in the extremities, bradycardia, troubled breathing, stomach pain, nausea, dizziness, vomiting, fatigue, jaundice-like symptoms, low fever, skin rashes, headache and insomnia.

Precautions

Entecavir is contraindicated in patients with AIDS/HIV, renal disorder, liver disorder, CHF and hepatic transplanted patients.

Special Precautions

Information not available

Other Drug Interactions

Entecavir may interact with rifampin, anti-viral drugs, amphotericin-B, immunosuppressive drugs, sirolimus and pentamidine.

Other Interactions

Information not available

Dosage

For compensated liver disease (chronic hepatitis B viral infection) with nucleoside treatment-naïve adults, 0.5 mg/day should be considered. For lamivudine co-treated patients or telbivudine-resistant patients, 1 mg, once daily should be considered.
For chronic hepatitis B viral infection patients (compensated liver disease), consider administration of 1 mg/day dose.

Food(before/after)

Entecavir should be taken at least 2 hours before meals intake

List of Contraindications

Entecavir and Pregnancy

Contraindicated in pregnancy
FDA pregnancy category C. Entecavir may or may not be harmful to an unborn fetus. Consult your physician if you are in gestation or planning to have a baby.

Entecavir and Lactation

Nursing mothers should consult the healthcare provider before Entecavir treatment.

Entecavir and Children

Information not available

Entecavir and Geriatic

Information not available

Entecavir and Other Contraindications

Information not available

Storage

Store at 20-25°C.

Lab interference

Store at 20-25°C.

Entecavir brands in India:

Baraclude Entavir Entehep

© 2011-2020 DrugsUpdate.com from UPilot INC. Disclaimer | Site Map

Feedback
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.